Amgen shares down as heart failure drug disappoints in phase 3 trialShares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug Share XAmgen shares down as heart failure drug disappoints in phase 3 trialhttps://pharmaphorum.com/news/amgen-shares-down-7-after-heart-failure-drug-disappoints-in-phase-3-trial/
RHYTHM AI cleared for large trial of atrial fibrillation mapping toolUK-based RHYTHM AI is to go ahead with a larger clinical trial of its artificial intelligence (AI)-driven system, Share XRHYTHM AI cleared for large trial of atrial fibrillation mapping toolhttps://pharmaphorum.com/news/rhythm-ai-cleared-for-large-trial-of-atrial-fibrillation-mapping-tool/
Regeneron’s cholesterol drug evinacumab claims February FDA dateThe FDA has started a speedy review of Regeneron’s ANGPTL3-targeting antibody evinacumab for a rare, inherited disorder that Share XRegeneron’s cholesterol drug evinacumab claims February FDA datehttps://pharmaphorum.com/news/regenerons-cholesterol-drug-evinacumab-claims-february-fda-date/
AZ picks up $350m after selling hypertension drugsAstraZeneca has picked up a $350m windfall after selling off five hypertension medicines to generics specialist Atnahs Pharma. Share XAZ picks up $350m after selling hypertension drugshttps://pharmaphorum.com/news/az-picks-up-350m-after-selling-hypertension-drugs/
FDA approves Caption Health’s AI-driven cardiac ultrasound softwareThe FDA has approved software from medical artificial intelligence (AI) firm Caption Health, that allows medical professionals without Share XFDA approves Caption Health’s AI-driven cardiac ultrasound softwarehttps://pharmaphorum.com/news/fda-approves-caption-healths-ai-driven-cardiac-imaging-software/
NICE backs Medtronic’s AF monitor in post-stroke patientsEngland’s NHS could prevent hundreds of strokes of unknown cause with a new implantable monitor that transmits data Share XNICE backs Medtronic’s AF monitor in post-stroke patientshttps://pharmaphorum.com/news/nice-backs-medtronics-af-monitor-in-post-stroke-patients/
AZ axes phase 3 heart disease trial of fish oil drug EpanovaAstraZeneca has axed a large late-stage trial for its heart disease drug Epanova in patients with mixed dyslipidemia Share XAZ axes phase 3 heart disease trial of fish oil drug Epanovahttps://pharmaphorum.com/news/az-axes-phase-3-trial-in-heart-disease/
AZ and Novoheart collaborate on ‘heart in a jar’, to develop new HF drugsStem cell biotech Novoheart is to collaborate with AstraZeneca to develop a “heart in a jar” that will Share XAZ and Novoheart collaborate on ‘heart in a jar’, to develop new HF drugshttps://pharmaphorum.com/news/az-and-novoheart-collaborate-on-heart-in-a-jar-to-d/
Novartis eyes $5bn The Medicines Company acquisition – reportsNovartis is leading a group of companies that are considering buying US pharma The Medicines Company searching for Share XNovartis eyes $5bn The Medicines Company acquisition – reportshttps://pharmaphorum.com/news/novartis-eyes-5bn-the-medicines-company-acquisition-reports/
